Getty Images/John-Francis Bourke
Amylin cut its San Diego workforce by 25 percent in November 2008. About 340 employees were laid off.
A local company that laid off hundreds of workers last year sharpened its budget knife again.
In other news, the biotechnology company Amylin Pharmaceuticals applied for Food and Drug Administration approval of its once-weekly diabetes treatment. The drug candidate exenatide LAR, an extended version of the twice-daily injectable drug Byetta, is being viewed by Wall Street as a way for Amylin to reinvigorate sales. The drug's competition would likely include Novo Nordisk's once-daily treatment Liraglutide, which is currently under FDA review.